Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII

Author(s): Fatemeh Sayyadipour, Naser Amirizadeh, Arezoo Oodi, Masoud Khalili, Fakhredin Saba*

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 20 , Issue 2 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Aims: Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. Erythrocytes may prevent rapid removal of drugs from plasma. Erythrocytes are biocompatible and non-immunogenic drug delivery. In this study, in vitro activity of FVIII encapsulated by human erythrocytes was investigated.

Methods: FVIII was loaded into erythrocytes using the hypo-osmotic dialysis technique. FVIII activity assay has been analyzed using Activated Partial Thromboplastin Time (APTT). Presence of FVIII on erythrocytes was detected by western blotting and flowcytometry using specific monoclonal antibody (abcam, U.K) against FVIII. Moreover, the osmotic fragility and hematologic parameters of FVIII-loaded carrier erythrocytes were measured.

Results: Our results indicated that FVIII could not cross the membrane, where plenty of FVIII was found on the surface of the carrier erythrocyte. Flow cytometery results showed that 11% of the loaded carrier erythrocytes was positive for FVIII protein on their surface.

The greatest activation of FVIII in both groups including lysate and non-lysate FVIII-loaded RBCs was observed on the first day, and the coagulant activity of this factor was gradually reduced on days 3 and 5. In 1:50 dilution of both groups, significant differences in FVIII activity were observed in 1:50 dilution of both groups, especially on the 5th day.

Conclusion: This study aims to introduce erythrocytes as appropriate carriers for FVIII to prolong the dosing intervals in the effective and safe levels for a relatively longer time.

Keywords: Factor VIII, erythrocyte, drug delivery, hemophilia A, erythrocytes, nucleotide.

Oldenburg, J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood, 2015, 125(13), 2038-2044.
[] [PMID: 25712992]
Witmer, C.; Young, G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther. Adv. Hematol., 2013, 4(1), 59-72.
[] [PMID: 23610614]
Porada, C.D.; Almeida-Porada, G. Treatment of hemophilia a in utero and postnatally using sheep as a model for cell and gene delivery. J. Genet. Syndr. Gene Ther., 2012, S1, S1.
[PMID: 23264887]
(a)Muzykantov, V.R. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv., 2010, 7(4), 403-427.
[] [PMID: 20192900]
(b)Saba, F.; Saki, N.; Khodadi, E.; Soleimani, M. Crosstalk between catecholamines and erythropoiesis. Front. Biol., 2017, 12(2), 103-115.
(a)Sun, Y.; Su, J.; Liu, G.; Chen, J.; Zhang, X.; Zhang, R.; Jiang, M.; Qiu, M. Advances of blood cell-based drug delivery systems. Eur. J. Pharm. Sci., 2017, 96, 115-128.
[] [PMID: 27496050]
(b)Gupta, N.; Patel, B.; Ahsan, F. Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm. Res., 2014, 31(6), 1553-1565.
[] [PMID: 24449438]
(c)Parodi, A.; Quattrocchi, N.; van de Ven, A.L.; Chiappini, C.; Evangelopoulos, M.; Martinez, J.O.; Brown, B.S.; Khaled, S.Z.; Yazdi, I.K.; Enzo, M.V.; Isenhart, L.; Ferrari, M.; Tasciotti, E. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol., 2013, 8(1), 61-68.
[] [PMID: 23241654]
(d)Chessa, L.; Leuzzi, V.; Plebani, A.; Soresina, A.; Micheli, R.; D’Agnano, D.; Venturi, T.; Molinaro, A.; Fazzi, E.; Marini, M.; Ferremi Leali, P.; Quinti, I.; Cavaliere, F.M.; Girelli, G.; Pietrogrande, M.C.; Finocchi, A.; Tabolli, S.; Abeni, D.; Magnani, M. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J. Rare Dis., 2014, 9, 5.
[] [PMID: 24405665]
(e)Anselmo, A.C.; Gupta, V.; Zern, B.J.; Pan, D.; Zakrewsky, M.; Muzykantov, V.; Mitragotri, S. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano, 2013, 7(12), 11129-11137.
[] [PMID: 24182189]
Hamidi, M.; Azimi, K.; Mohammadi-Samani, S. Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: phenytoin and bovine serum albumin (BSA). J.Pharm. Sci., 2011, 14(1), 46-59.
Sparrow, R.L. Red blood cell storage and transfusion-related immunomodulation. Blood Trans., 2010, 8(3), s26-30.
Garín, M-I.; López, R-M.; Sanz, S.; Pinilla, M.; Luque, J. Erythrocytes as carriers for recombinant human erythropoietin. Pharm. Res., 1996, 13(6), 869-874.
[] [PMID: 8792424]
Hamidi, M.; Zarrin, A.H.; Foroozesh, M.; Zarei, N.; Mohammadi-Samani, S. Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. Int. J. Pharm., 2007, 341(1-2), 125-133.
[] [PMID: 17512685]
(a)Arora, S.; Kolte, S.; Dhupia, J. Hemolyzed samples should be processed for coagulation studies: The study of hemolysis effects on coagulation parameters. Ann. Med. Health Sci. Res., 2014, 4(2), 233-237.
[] [PMID: 24761244]
(b)Laga, A.C.; Cheves, T.A.; Sweeney, J.D. The effect of specimen hemolysis on coagulation test results. Am. J. Clin. Pathol., 2006, 126(5), 748-755.
[] [PMID: 17050072]
Sinauridze, E.I.; Vuimo, T.A.; Kulikova, E.V.; Shmyrev, I.I.; Ataullakhanov, F.I. A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX. Med. Sci. Monit., 2010, 16(10), PI19-PI26.
[PMID: 20885362]

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [131 - 137]
Pages: 7
DOI: 10.2174/1871529X19666190918141859

Article Metrics

PDF: 43